Therapeutic Approaches for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (All), a Review on Monoclonal Antibodies and Targeted Therapies Publisher Pubmed



Hosseini M¹ ; Jafari L^{1, 2} ; Yami A¹ ; Gharehbaghian A¹ Show Affiliations
Source: Indian Journal of Cancer Published:2022

Abstract

Acute lymphoblastic leukemia (ALL) is the malignant transformation of lymphoid progenitors that affects both children and adults. Although the outcome of pediatric patients has been improved dramatically, there are still many challenges in the treatment of adults. Patients with primary resistant or relapsed disease have the worst outcome and despite the administration of intensified multi-agents chemotherapies, the outcome of this group remains very poor. Accordingly, the development of novel therapeutic options is considered necessary. Having a comprehensive insight into the pathophysiology of ALL and aberrant signaling pathways is crucial for introducing effective targeted therapies. Combination therapies with new drugs and innovative targeted therapies with the aim of affecting the main aberrant signaling pathways in the disease are considered as new approaches. Here we tried to have a comprehensive review on the potential molecular targets in the treatment of refractory/relapsed ALL and the current therapeutic agents. © 2022 Wolters Kluwer Medknow Publications. All rights reserved.